Last reviewed · How we verify
injectable naltrexone
Injectable naltrexone, marketed by Lifespan, holds a position in the treatment landscape for its primary indication, though specific details on its market share are not provided. A key strength of the drug is its patent protection, which extends to 2028, providing a period of exclusivity for the key composition. The primary risk is the lack of detailed revenue data, which may affect investment and strategic planning decisions.
At a glance
| Generic name | injectable naltrexone |
|---|---|
| Also known as | Vivitrol |
| Sponsor | Lifespan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions (NA)
- Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (PHASE4)
- iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers (PHASE1)
- Long-acting Naltrexone for Pre-release Prisoners (PHASE3)
- Promoting Alcohol Treatment Engagement Post-hospitalization (NA)
- Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail (PHASE2, PHASE3)
- Naltrexone in AUD Reward Drinkers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- injectable naltrexone CI brief — competitive landscape report
- injectable naltrexone updates RSS · CI watch RSS
- Lifespan portfolio CI